This list is an analysis based on recent market events. It's not an investment recommendation.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
FAQs
What is Scinai Immunotherapeutics stock price today?▼
The current price of SCNI is $0.47 USD — it has decreased by -9.05% in the past 24 hours. Watch Scinai Immunotherapeutics stock price performance more closely on the chart.
What is Scinai Immunotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Scinai Immunotherapeutics stocks are traded under the ticker SCNI.
Is Scinai Immunotherapeutics stock price growing?▼
SCNI stock has fallen by -12.91% compared to the previous week, the month change is a -64.54% fall, over the last year Scinai Immunotherapeutics has showed a -96.63% decrease.
What is Scinai Immunotherapeutics market cap?▼
Today Scinai Immunotherapeutics has the market capitalization of 638,182.32
What is Scinai Immunotherapeutics revenue for the last year?▼
Scinai Immunotherapeutics revenue for the last year amounts to 949,000 USD.
What is Scinai Immunotherapeutics net income for the last year?▼
SCNI net income for the last year is 1.57M USD.
How many employees does Scinai Immunotherapeutics have?▼
As of November 2, 2026, the company has 45 employees.
In which sector is Scinai Immunotherapeutics located?▼
Scinai Immunotherapeutics operates in the Health & Wellness sector.
When did Scinai Immunotherapeutics complete a stock split?▼
The last stock split for Scinai Immunotherapeutics was on May 21, 2024 with a ratio of 1:10.
Where is Scinai Immunotherapeutics headquartered?▼
Scinai Immunotherapeutics is headquartered in JERUSALEM, Israel.